Somatostatin Analogs in Clinical Practice: a Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Mar 4

PMID 32121432

Citations 89

Authors

Mariana Gomes-Porras

Jersy Cardenas-Salas

Cristina Alvarez-Escola

Affiliations

Soon will be listed here.

Abstract

Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of somatotropinomas, thyrotropinomas, and functioning and non-functioning gastroenteropancreatic neuroendocrine tumors. They should also be considered an effective and safe therapeutic alternative to corticotropinomas, gonadotropinomas, and prolactinomas resistant to dopamine agonists. Somatostatin analogs have also shown to be useful in the treatment of other endocrine diseases (congenital hyperinsulinism, Graves' orbitopathy, diabetic retinopathy, diabetic macular edema), non-endocrine tumors (breast, colon, prostate, lung, and hepatocellular), and digestive diseases (chronic refractory diarrhea, hepatorenal polycystosis, gastrointestinal hemorrhage, dumping syndrome, and intestinal fistula).

Citing Articles

Evaluation of fluid status in patients with acromegaly through bioelectrical impedance vector analysis: a cross-sectional study.

Varaldo E, Prencipe N, Berton A, Cuboni D, Aversa L, Sibilla M J Endocrinol Invest. 2025; .

PMID: 39954196 DOI: 10.1007/s40618-025-02541-4.

Neuroendocrine tumors and diabetes mellitus: which treatment and which effect.

Mazzilli R, Zamponi V, Mancini C, Giorgini B, Golisano B, Mikovic N Endocrine. 2025; .

PMID: 39752043 DOI: 10.1007/s12020-024-04149-9.

[Zr]Zr-DFO-TOC: a novel radiopharmaceutical for PET imaging of somatostatin receptor positive neuroendocrine tumors.

Sanwick A, Haugh K, Williams E, Perry K, Thiele N, Chaple I EJNMMI Radiopharm Chem. 2024; 9(1):88.

PMID: 39693037 PMC: 11655904. DOI: 10.1186/s41181-024-00320-9.

Exploring key features of selectivity in somatostatin receptors through molecular dynamics simulations.

Guccione C, Gervasoni S, Ozturk I, Bosin A, Ruggerone P, Malloci G Comput Struct Biotechnol J. 2024; 23:1311-1319.

PMID: 39660216 PMC: 11630666. DOI: 10.1016/j.csbj.2024.03.005.

Peptide-Based Biomaterials for Combatting Infections and Improving Drug Delivery.

Lombardi L, Li J, Williams D Pharmaceutics. 2024; 16(11).

PMID: 39598591 PMC: 11597775. DOI: 10.3390/pharmaceutics16111468.

References

Coopmans E, van Meyel S, Pieterman K, van Ipenburg J, Hofland L, Donga E . Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma. Eur J Endocrinol. 2019; 181(2):K21-K27. DOI: 10.1530/EJE-19-0279. View

Tirosh A, Stemmer S, Solomonov E, Elnekave E, Saeger W, Ravkin Y . Pasireotide for malignant insulinoma. Hormones (Athens). 2016; 15(2):271-276. DOI: 10.14310/horm.2002.1639. View

Franck S, Gatto F, van der Lely A, Janssen J, Dallenga A, Nagtegaal A . Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant. Neuroendocrinology. 2016; 105(1):44-53. PMC: 5475231. DOI: 10.1159/000448429. View

Tack J, Aberle J, Arts J, Laville M, Oppert J, Bender G . Safety and efficacy of pasireotide in dumping syndrome-results from a phase 2, multicentre study. Aliment Pharmacol Ther. 2018; 47(12):1661-1672. DOI: 10.1111/apt.14664. View

Maiter D . Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology. 2018; 109(1):42-50. DOI: 10.1159/000495775. View

Luque-Ramirez M, Carreno A, Alvarez Escola C, del Pozo Pico C, Varela Da Costa C, Fajardo Montanana C . [The OASIS study: therapeutic management of acromegaly in standard clinical practice. Assessment of the efficacy of various treatment strategies]. Endocrinol Nutr. 2011; 58(9):478-86. DOI: 10.1016/j.endonu.2011.09.002. View

Hyer S, Sharp P, Brooks R, Burrin J, Kohner E . Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. Acta Endocrinol (Copenh). 1989; 120(2):187-94. DOI: 10.1530/acta.0.1200187. View

Ruszniewski P, Valle J, Lombard-Bohas C, Cuthbertson D, Perros P, Holubec L . Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Dig Liver Dis. 2016; 48(5):552-558. DOI: 10.1016/j.dld.2015.12.013. View

Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L . Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab. 2001; 86(1):140-5. DOI: 10.1210/jcem.86.1.7099. View

10.

Jorgensen J, Feldt-Rasmussen U, Frystyk J, Chen J, Kristensen L, Hagen C . Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005; 90(10):5627-31. DOI: 10.1210/jc.2005-0531. View

11.

Zarogoulidis K, Eleftheriadou E, Kontakiotis T, Gerasimou G, Zarogoulidis P, Sapardanis I . Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients. Lung Cancer. 2011; 76(1):84-8. DOI: 10.1016/j.lungcan.2011.09.014. View

12.

Buscail L, Delesque N, Esteve J, Saint-Laurent N, Prats H, Clerc P . Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A. 1994; 91(6):2315-9. PMC: 43361. DOI: 10.1073/pnas.91.6.2315. View

13.

Lamberts S, Lely A, Hofland L . New somatostatin analogs: will they fulfil old promises?. Eur J Endocrinol. 2002; 146(5):701-5. DOI: 10.1530/eje.0.1460701. View

14.

de Herder W, Lamberts S . Is there a role for somatostatin and its analogs in Cushing's syndrome?. Metabolism. 1996; 45(8 Suppl 1):83-5. DOI: 10.1016/s0026-0495(96)90091-8. View

15.

Miller G, Alexander J, Bikkal H, Katznelson L, Zervas N, Klibanski A . Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab. 1995; 80(4):1386-92. DOI: 10.1210/jcem.80.4.7714115. View

16.

Colucci R, Blandizzi C, Ghisu N, Florio T, Del Tacca M . Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation. Br J Pharmacol. 2008; 155(2):198-209. PMC: 2538699. DOI: 10.1038/bjp.2008.268. View

17.

Trainer P, Drake W, Katznelson L, Freda P, Lely A, Dimaraki E . Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000; 342(16):1171-7. DOI: 10.1056/NEJM200004203421604. View

18.

Zhou X, Tripathi D, Song T, Shao L, Han B, Zhu J . Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018; 97(48):e13437. PMC: 6283114. DOI: 10.1097/MD.0000000000013437. View

19.

Katznelson L, Laws Jr E, Melmed S, Molitch M, Murad M, Utz A . Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(11):3933-51. DOI: 10.1210/jc.2014-2700. View

20.

Rubin J, Ajani J, Schirmer W, Venook A, Bukowski R, Pommier R . Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999; 17(2):600-6. DOI: 10.1200/JCO.1999.17.2.600. View